+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Neuropathy Market Research Report by Treatment Type, by Distribution channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4989733
  • Report
  • June 2020
  • Region: Global
  • 217 pages
  • 360iResearch™
UP TO OFF
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Diabetic Neuropathy Market to Grow USD 2,731.31 Million by 2025, at a CAGR of 5.32%

FEATURED COMPANIES

  • ACTAVIS
  • Cephalon Inc
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Johnson and Johnson
  • MEDA Pharma GmBH & Co. KG
  • MORE
The Global Diabetic Neuropathy Market is expected to grow from USD 2,000.29 Million in 2019 to USD 2,731.31 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.32%.

Market Segmentation & Coverage:

This research report categorizes the Diabetic Neuropathy to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Treatment Type, the Diabetic Neuropathy Market is examined across Drugs, Physiotherapy, and Radiotherapy. The Drugs further studied across Analgesics, Anticonvulsants, and Antidepressant.

On the basis of Disorder Type, the Diabetic Neuropathy Market is examined across Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy, and Proximal Neuropathy.

On the basis of Distribution channel, the Diabetic Neuropathy Market is examined across Clinics, Hospitals, Online Pharmacy, and Retail Pharmacy.

On the basis of Geography, the Diabetic Neuropathy Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Diabetic Neuropathy Market including ACTAVIS, Cephalon Inc, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Johnson and Johnson, MEDA Pharma GmBH & Co. KG, NeuroMetrix, and Pfizer Inc.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Diabetic Neuropathy Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetic Neuropathy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetic Neuropathy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetic Neuropathy Market?
4. What is the competitive strategic window for opportunities in the Global Diabetic Neuropathy Market?
5. What are the technology trends and regulatory frameworks in the Global Diabetic Neuropathy Market?
6. What are the modes and strategic moves considered suitable for entering the Global Diabetic Neuropathy Market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ACTAVIS
  • Cephalon Inc
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Johnson and Johnson
  • MEDA Pharma GmBH & Co. KG
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Treatment Type Outlook
3.3. Disorder Type Outlook
3.4. Distribution channel Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Diabetic Neuropathy Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Diabetic Neuropathy Market, By Treatment Type
7.1. Introduction
7.2. Drugs
7.2.1. Analgesics
7.2.1.1. NSAIDs
7.2.1.2. Opioids
7.2.1.3. Topical
7.2.2. Anticonvulsants
7.2.2.1. Gabapentin
7.2.2.2. Pregabalin
7.2.2.3. Topimarate
7.2.3. Antidepressant
7.2.3.1. SNRIs
7.2.3.2. SSRIs
7.2.3.3. TCAs
7.3. Physiotherapy
7.4. Radiotherapy

8. Global Diabetic Neuropathy Market, By Disorder Type
8.1. Introduction
8.2. Autonomic Neuropathy
8.3. Focal Neuropathy
8.4. Peripheral Neuropathy
8.5. Proximal Neuropathy

9. Global Diabetic Neuropathy Market, By Distribution channel
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Online Pharmacy
9.5. Retail Pharmacy

10. Americas Diabetic Neuropathy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Diabetic Neuropathy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand

12. Europe, Middle East & Africa Diabetic Neuropathy Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding

14. Company Usability Profiles
14.1. ACTAVIS
14.2. Cephalon Inc
14.3. Eli Lilly and Company
14.4. GlaxoSmithKline
14.5. Janssen Pharmaceuticals, Inc
14.6. Johnson and Johnson
14.7. MEDA Pharma GmBH & Co. KG
14.8. NeuroMetrix
14.9. Pfizer Inc

15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3
  • ACTAVIS
  • Cephalon Inc
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Janssen Pharmaceuticals, Inc
  • Johnson and Johnson
  • MEDA Pharma GmBH & Co. KG
  • NeuroMetrix
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll